Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Johnson and Johnson
McKesson
Dow
Baxter

Last Updated: November 23, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BRIMONIDINE TARTRATE; TIMOLOL MALEATE

See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Brimonidine Tartrate; Timolol Maleate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00435058 Visual Function Changes After Intraocular Pressure Reduction Completed University of Sao Paulo N/A 2005-09-01 During the glaucomatous disease process, subpopulations of cells may be dead, damaged or healthy. Visual function changes could be observed due to a recovering of the suffering ganglion cells after the intraocular pressure reduction. This study aims at evaluating the correlation between intraocular pressure reduction and visual function changes in glaucoma patients after using antiglaucoma medications.
NCT00698945 Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG) Completed Bp Consulting, Inc Phase 4 2008-06-01 To assess the additional benefit of common adjunctive classes on the diurnal IOP curve in patients assessed as needing additional treatment to reach target intraocular pressure (IOP). To demonstrate superiority of IOP control with Istalol 0.5% QD compared to Brimonidine Tartrate 0.2% BID as adjunctive therapy in adults with uncontrolled IOP's (determined by P.I. based on target pressures) currently treated with Latanoprost 0.05% in the study eye(s).
NCT00811564 An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects Completed Allergan Phase 4 2008-12-01 A three-month evaluation comparing the safety and efficacy of a fixed combination of 0.2% brimonidine tartrate/0.5% timolol maleate with that of latanoprost 0.005%, a prostaglandin analogue in glaucoma or ocular hypertension subjects
NCT00811850 Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow Completed Allergan Phase 4 2008-12-01 A 10 week evaluation, crossover design study including a 3 week washout period between treatments, to determine the effects of Combigan® (fixed combination brimonidine tartrate 0.2%/timolol maleate 0.5%) and Cosopt® (fixed combination dorzolamide hydrochloride-timolol maleate ophthalmic solutions) on ocular blood flow as measured by retrobulbar blood flow.
NCT01284166 Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension Withdrawn Allergan Phase 3 2013-07-01 This study will investigate the safety and efficacy of Triple Combination Therapy with dorzolamide hydrochloride/brimonidine tartrate/timolol ophthalmic solution in patients with glaucoma or ocular hypertension who have elevated IOP on dorzolamide hydrochloride/timolol maleate combination therapy.
NCT01987752 Safety and Efficacy of Combigan® Ophthalmic Solution in Korea Completed Allergan N/A 2009-01-01 This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and efficacy of Combigan® (brimonidine tartrate/timolol maleate) Ophthalmic Solution in patients with Open Angle Glaucoma or Ocular hypertension with insufficient response to local beta blockers treated as per standard of care in clinical practice.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Brimonidine Tartrate; Timolol Maleate

Condition Name

Condition Name for Brimonidine Tartrate; Timolol Maleate
Intervention Trials
Glaucoma 4
Ocular Hypertension 4
Glaucoma, Open-Angle 1
Open-Angle Glaucoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Brimonidine Tartrate; Timolol Maleate
Intervention Trials
Ocular Hypertension 4
Glaucoma 3
Hypertension 3
Glaucoma, Open-Angle 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Brimonidine Tartrate; Timolol Maleate

Trials by Country

Trials by Country for Brimonidine Tartrate; Timolol Maleate
Location Trials
United States 3
Korea, Republic of 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Brimonidine Tartrate; Timolol Maleate
Location Trials
Indiana 1
New York 1
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Brimonidine Tartrate; Timolol Maleate

Clinical Trial Phase

Clinical Trial Phase for Brimonidine Tartrate; Timolol Maleate
Clinical Trial Phase Trials
Phase 4 3
Phase 3 1
N/A 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Brimonidine Tartrate; Timolol Maleate
Clinical Trial Phase Trials
Completed 5
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Brimonidine Tartrate; Timolol Maleate

Sponsor Name

Sponsor Name for Brimonidine Tartrate; Timolol Maleate
Sponsor Trials
Allergan 4
University of Sao Paulo 1
Bp Consulting, Inc 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Brimonidine Tartrate; Timolol Maleate
Sponsor Trials
Industry 4
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Express Scripts
Boehringer Ingelheim
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.